{
  "id": 546448,
  "title": "Efferon is ‘selling time’ in the race to treat sepsis",
  "url": "https://urgent.news/2026/08/11/efferon-is-selling-time-in-the-race-to-treat-sepsis",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-11T08:00:00.000Z",
  "source": {
    "name": "Tech.eu",
    "slug": "tech-eu",
    "url": "https://tech.eu/2026/08/11/efferon-is-selling-time-in-the-race-to-treat-sepsis/"
  },
  "original_language": "en",
  "account": "Every minute, one life in Europe succumbs to sepsis or septic shock. Sepsis occurs when the body's response to an infection damages its own tissues and organs, potentially leading to shock, multi-organ failure, and ultimately death, particularly if diagnosed and treated late. This is the ultimate pathway to death for many infectious diseases, including viral infections like SARS-CoV-2/COVID-19. In 2021, a staggering 166 million cases of sepsis were reported globally, claiming the lives of 21.4 million people, accounting for nearly one-third of all global fatalities. One company striving to combat this issue is Austria-based Efferon, which is developing technology aimed at intervening in the inflammatory response that exacerbates sepsis. Founded in 2016, Efferon's blood-purification devices complement existing treatments by removing bacterial toxins and excessive inflammatory molecules from the bloodstream, helping stabilize critically ill patients with sepsis and septic shock. CEO and co-founder Dima Romashin emphasizes the critical role of time in sepsis diagnosis and treatment, stating that patients can deteriorate rapidly, and the inflammatory response may persist even after addressing the underlying infection. Current sepsis care primarily focuses on controlling the initial infection and supporting failing organs, but no single treatment directly targets the complex, dysregulated immune response that drives sepsis. Instead, Efferon's technology aims to remove bacterial toxins and excessive inflammatory mediators from the blood, allowing conventional therapies to work more effectively. Efferon currently offers two main devices: Efferon LPS, a single-use blood-purification cartridge designed for adult ICU patients with sepsis and septic shock, and Efferon NEO, tailored for neonatal and pediatric intensive care patients. Efferon LPS functions like a specialized filter outside the body, removing endotoxin (LPS) from Gram-negative bacteria and excessive inflammatory molecules, including cytokines such as IL-6 and IL-1β. Meanwhile, Efferon NEO, approved for use in Europe since April 2024, is specifically designed for treating pediatric patients with sepsis and septic shock, addressing their unique physiological needs due to smaller blood volumes. Romashin emphasizes that Efferon's approach is unique, targeting both the \"flame\" (LPS) and \"smoke\" (cytokines) of the inflammatory response simultaneously, potentially making the treatment process quicker and more effective. Despite competition from other companies working on similar technologies, Efferon stands out by addressing both components of the inflammatory response together, rather than solely focusing on the underlying infection.",
  "summary": "Every minute one person in Europe dies from sepsis or septic shock. Sepsis arises when the body’s response to an infection injures its own tissues and organs. It may lead to shock, multi-organ failure...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}